An observational study in Colorectal Liver Metastases, Colorectal Neoplasms and Liver Neoplasms, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Anhui Provincial Hospital · Observational
Among 1,132 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 602 under way, 67 of them phase 3. Colorectal Neoplasms · China.
Among the 1,132 studies in Colorectal Neoplasms with a site in China, this one is the 157th largest by planned enrollment of the 242 observational ones, is one of 31 that started in 2017, is one of 242 observational ones, reaches primary completion later than 275 of the 601 other live ones, and was the 1,099th registered.
6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.
This study's planned enrollment of 205 is below the median of 250 across 1,440 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →526 of the 1,132 studies in Colorectal Neoplasms with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →1,132 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 31 started in 2017.
Median enrollment 80 across the 888 interventional studies, 400 across the 242 observational. Of the 212 that completed or were terminated, 27 (13%) have results posted.
247 of 1,132 have an industry lead sponsor. The 10 most frequent:
Anhui Provincial Hospital is the lead sponsor of 135 studies on the registry; 101 are open to participants now.
Anhui Provincial Hospital has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
145 of the studies in Colorectal Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06008119Phase 3Shanghai Kechow Pharma, Inc.Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | 2026-12-24 |
| NCT05171660Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCombination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | 2026-12-30 |
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT05086614Phase 3Fudan UniversityThymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer | 2027-03-31 |
Among the 1,132 studies in Colorectal Neoplasms with a site in China, from their registry updates:
The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline indicators for patients with colorectal liver metastases (CRLM) after surgery. By combining micro-level radiomics signatures reflecting tumor micro-heterogeneity with macro-level clinical parameters (such as liver function and tumor biomarkers), the study aims to accurately evaluate individual post-operative prognostic risks. This quantitative tool will provide reliable decision support for clinicians to customize post-operative follow-up and personalized adjuvant treatment strategies.
This study is based on a strictly screened multicenter cohort of patients with colorectal liver metastases who underwent surgical intervention. First, high-throughput quantitative features are automatically extracted from the 3D regions of interest (ROIs) segmented based on pre-operative magnetic resonance imaging (MRI). Advanced machine learning dimensionality reduction algorithms are subsequently applied to eliminate redundant variables and select core imaging signatures that deeply reflect tumor micro-heterogeneity, microvascular proliferation, and invasive status. On this basis, these micro-level radiomics features are fused with macro-level clinical parameters, including liver function indexes and tumor load markers. Multivariable survival analysis models are performed to identify independent prognostic factors, which are further used to develop a visual and intuitive predictive nomogram tool. Finally, time-dependent evaluation metrics and an external validation cohort will be utilized to systematically test the dynamic predictive performance and cross-platform generalizability of the model. This multimodal dual-track data paradigm aims to achieve a non-invasive and efficient "digital optical biopsy" approach for prognostic evaluation.
The study population consists of adult patients diagnosed with colorectal liver metastases who underwent surgical resection across multiple participating clinical centers, featuring high-quality preoperative liver MRI scans and complete clinical follow-up histories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age >= 18 years old. Confirmed diagnosis of colorectal cancer with liver (CRLM). Underwent surgical resection for colorectal liver metastases. Preoperative liver magnetic resonance imaging (MRI) was performed with high-quality images available for 3D radiomics feature extraction.
Complete baseline clinical, laboratory, and post-operative follow-up survival data.
Exclusion Criteria:
Patients who received local ablation only (such as radiofrequency ablation) without surgical resection.
Preoperative MRI images with severe artifacts or poor quality that prevent high-throughput radiomics analysis.
Concurrent history of other primary malignant neoplasms. Missing key clinical variables or lost to follow-up immediately after surgical intervention.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A multicenter cohort consisting of patients with colorectal liver metastases who underwent surgical resection. Preoperative magnetic resonance imaging (MRI) is utilized for 3D modeling and three-dimensional reconstruction of the liver and lesions, from which key spatial/morphological features and systemic clinical parameters are analyzed to predict post-operative recurrence-free survival.
Procedure: Multimodal Predictive Evaluation
Observational and non-invasive assessment based on preoperative MRI-derived 3D modeling and three-dimensional lesion reconstruction, combined with clinical parameters, to build a survival prediction model. No experimental intervention is assigned.
Recurrence-Free Survival (RFS)
Recurrence-free survival (RFS) is defined as the time from the date of surgical resection to the date of first tumor recurrence (local, regional, or distant) or death from any cause, whichever occurs first.
Time frame: Up to 5 years post-surgery
Plan to share: No — To protect participant privacy and comply with institutional data governance policies, individual participant data from this retrospective study will not be publicly shared.
No publications or documents are linked to this record.
Started Feb 2017 (actual). Primary completion is estimated for Sep 2026, 115 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.